New stem cell transplant for children with high-risk blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a special stem cell transplant from a half-matched family donor, designed to reduce rejection and infection risk. It may include a targeted drug (blinatumomab) to help kill remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years old or younger.
- You must have a high-risk blood cancer (like certain types of leukemia, MDS, or other rare blood cancers).
- You must have a family member who is at least 18 years old and a half-matched donor (one parent is usually a match).
- Your heart, kidneys, lungs, and liver must be working well enough for transplant.
- You must not have had a stem cell transplant before.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
This trial studies a type of stem cell transplant (bone marrow transplant) that uses a donor who is only half-matched to the patient, often a parent or sibling. It is for children and young adults with certain blood diseases, including sickle cell disease, thalassemia, bone marrow failure, and immune disorders. The transplant aims to replace the diseased blood-forming cells with healthy ones from the donor.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.